Edgewise Therapeutics inc (EWTX) - News Archive

Edgewise Therapeutics Reports Promising Advancements Across Diverse Muscle and Cardiac Conditions Boulder, Colo. Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a pioneering biopharmaceutical firm specializing in muscle dis...

Navigating Uncharted Waters: Edgewise Therapeutics Journey in Rare Disease Research In the idyllic city of Boulder, nestled against the backdrop of the Rocky Mountains, Edgewise Therapeutics, Inc. (Nasdaq: EWTX) is stea...

Edgewise Therapeutics Clarifies Relationship With Dr. Han Phan Following FDA Warning Boulder, Colo. Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a forerunner in the biopharmaceutical landscape dedicated to combating musc...

In a recent announcement, Edgewise Therapeutics, a prominent biopharmaceutical company specializing in muscle disease treatment, revealed the initiation of the Phase 2 CIRRUS-HCM trial for their innovative oral medicati...

Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common StockBOULDER, Colo. - Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, has revealed the pricing details f...